HOME > BUSINESS
BUSINESS
- Fuji Yakuhin Files Hyperuricemia Candidate Dotinurad
December 26, 2018
- Fujifilm, MIT Launch Research Project on Oligonucleotide DDS
December 26, 2018
- INCJ Makes Further Investment in NapaJen Pharma
December 26, 2018
- RaQualia’s Tegoprazan Sublicensed to Vietnam’s Vimedimex
December 26, 2018
- Some Drug Makers Stop Distributing 2019 Calendars with Revised JPMA Code of Practice Set to Take Effect in January
December 25, 2018
- Takeda Completes M&A Bridge Re-Financing
December 25, 2018
- Mundipharma Files for Japan Approval of Anesthetic Remimazolam
December 25, 2018
- Kyoto Univ., Sumitomo Dainippon, Sumitomo Chemical Team Up for Research on iPS Cell Production
December 25, 2018
- Xtandi Smashes Primary Goal in Patients with mHSPC in PIII Trial
December 25, 2018
- Daiichi Sankyo Kicks Off 1st Combo Study for Its 2 AML Meds
December 21, 2018
- Fuji Pharma Invests US$50 Million in Alvotech to Boost Biosimilar Business in Japan
December 21, 2018
- ViiV’s HIV Drug Juluca Now Available in Japan
December 21, 2018
- Kowa Reps Continue Heavy GP Pitch for Parmodia in September: Anterio
December 21, 2018
- Taisho to Develop Overseas Biz in Asia and Europe through BMS’s Consumer Unit Buyout
December 21, 2018
- Fujifilm to Set Up New iPS Cell Production Facility in US, Start Operations in FY2019
December 21, 2018
- Life Science Institute Initiates Exploratory Clinical Trial of Muse Cell Product for Epidermolysis Bullosa
December 21, 2018
- Taisho to Acquire Bristol-Myers’s Consumer Health Unit
December 20, 2018
- Chugai’s Satralizumab Wins FDA Breakthrough Therapy Status
December 20, 2018
- ROS1/TRK Inhibitor Entrectinib Filed in Japan: Chugai
December 20, 2018
- Toray Sues Sawai, Fuso over Use Patent for Remitch OD Tablets
December 20, 2018
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
